-
公开(公告)号:US12221481B2
公开(公告)日:2025-02-11
申请号:US16877878
申请日:2020-05-19
Applicant: Novartis AG
Inventor: Brian Granda , Amy Rayo , Connie Hong , Dattananda Chelur , Haihui Lu , Regis Cebe , Sunyoung Jang
Abstract: The present disclosure provides CD19 binding molecules that specifically bind to CD19, including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD19 binding molecules, and pharmaceutical compositions comprising the CD19 binding molecules and the conjugates. The disclosure further provides methods of using the C19 binding molecules to treat diseases and disorders associated with expression of CD19. The disclosure yet further provides recombinant host cells engineered to express the CD19 binding molecules and methods of producing the CD19 binding molecules by culturing the host cells under conditions in which the CD19 binding molecules are expressed.
-
公开(公告)号:US12037378B2
公开(公告)日:2024-07-16
申请号:US17612993
申请日:2020-05-19
Applicant: NOVARTIS AG
Inventor: Barbara Brannetti , Dattananda Chelur , Brian Granda , Connie Hong
IPC: C07K14/705
CPC classification number: C07K14/70528
Abstract: The present disclosure provides CD2 binding molecules that specifically bind to CD2, including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD2 binding molecules, and pharmaceutical compositions comprising the CD2 binding molecules and the conjugates. The disclosure further provides methods of using the CD2 binding molecules to modulate CD2 signaling in order to treat a variety of immune (e.g., autoimmune), inflammatory and proliferative disorders. The disclosure yet further provides recombinant host cells engineered to express the CD2 binding molecules and methods of producing the CD2 binding molecules by culturing the host cells under conditions in which the CD2 binding molecules are expressed.
-
公开(公告)号:US20210139585A1
公开(公告)日:2021-05-13
申请号:US16877878
申请日:2020-05-19
Applicant: Novartis AG
Inventor: Brian Granda , Amy Rayo , Connie Hong , Dattananda Chelur , Haihui Lu , Regis Cebe , Sunyoung Jang
Abstract: The present disclosure provides CD19 binding molecules that specifically bind to CD19, including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD19 binding molecules, and pharmaceutical compositions comprising the CD19 binding molecules and the conjugates. The disclosure further provides methods of using the C19 binding molecules to treat diseases and disorders associated with expression of CD19. The disclosure yet further provides recombinant host cells engineered to express the CD19 binding molecules and methods of producing the CD19 binding molecules by culturing the host cells under conditions in which the CD19 binding molecules are expressed.
-
-